- Home
- DGHI vs IMAB Comparison
DGHI vs IMAB Comparison
Compare DGHI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGHI
- IMAB
- Stock Information
- Founded
- DGHI 2017
- IMAB 2014
- Country
- DGHI United States
- IMAB United States
- Employees
- DGHI N/A
- IMAB N/A
- Industry
- DGHI Finance: Consumer Services
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DGHI Finance
- IMAB Health Care
- Exchange
- DGHI Nasdaq
- IMAB Nasdaq
- Market Cap
- DGHI 90.1M
- IMAB 79.9M
- IPO Year
- DGHI N/A
- IMAB 2020
- Fundamental
- Price
- DGHI $1.17
- IMAB $0.82
- Analyst Decision
- DGHI Strong Buy
- IMAB Strong Buy
- Analyst Count
- DGHI 1
- IMAB 3
- Target Price
- DGHI $2.50
- IMAB $8.00
- AVG Volume (30 Days)
- DGHI 515.4K
- IMAB 223.4K
- Earning Date
- DGHI 04-02-2025
- IMAB 03-21-2025
- Dividend Yield
- DGHI N/A
- IMAB N/A
- EPS Growth
- DGHI N/A
- IMAB N/A
- EPS
- DGHI N/A
- IMAB N/A
- Revenue
- DGHI $42,146,057.00
- IMAB $569,464.00
- Revenue This Year
- DGHI N/A
- IMAB N/A
- Revenue Next Year
- DGHI N/A
- IMAB N/A
- P/E Ratio
- DGHI N/A
- IMAB N/A
- Revenue Growth
- DGHI 100.56
- IMAB N/A
- 52 Week Low
- DGHI $0.84
- IMAB $0.76
- 52 Week High
- DGHI $3.77
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- DGHI 33.09
- IMAB 33.87
- Support Level
- DGHI $1.13
- IMAB $0.78
- Resistance Level
- DGHI $1.49
- IMAB $0.93
- Average True Range (ATR)
- DGHI 0.22
- IMAB 0.06
- MACD
- DGHI -0.05
- IMAB -0.01
- Stochastic Oscillator
- DGHI 9.92
- IMAB 23.53
About DGHI Digihost Technology Inc. Common Subordinate Voting Shares
Digihost Technology Inc is a blockchain company focused on Bitcoin mining. The company's mining facility is located in Buffalo, New York, and is equipped with an 18.7 MVA 115,000-kilovolt ampere outdoor substation with an option to increase the power output to 42MVA.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).